Aortic Valve Replacement During Acute Rheumatic Fever A
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Frater, Robert
Oral History Interview with Robert Frater Cardiothoracic Surgeon St. Jude’s Medical Center FDA Oral History Program Final Edited Transcript May 2003 Table of Contents Oral History Abstract ...................................................................................................................... 2 Keywords ........................................................................................................................................ 2 Citation Instructions ........................................................................................................................ 2 Interviewer Biography ..................................................................................................................... 3 FDA Oral History Program Mission Statement .............................................................................. 3 Statement on Editing Practices ....................................................................................................... 3 Index ............................................................................................................................................... 4 Interview Transcript ........................................................................................................................ 5 Robert Frater Oral History 1 Oral History Abstract This interview was conducted in an effort to collect background information on the development of cardiothoracic surgery and heart valve design and surgical implantation. Dr. Frater was a pioneer in the development -
Balloon Aortic Valvuloplasty
Original Research Article Journal of Structural Heart Disease, May 2015, Received: December 8, 2014 Volume 1, Issue 1: 20-32 Accepted: December 15, 2014 Published online: May 2015 DOI: http://dx.doi.org/10.12945/j.jshd.2015.00009-14 Balloon Aortic Valvuloplasty Patient Selection and Technical Considerations Ted Feldman, MD, FESC, FACC, MSCAI*, Mohammad Sarraf, MD, Wes Pedersen, MD, FACC, FSCAI Evanston Hospital, NorthShore University Health System, Evanston, Illinois NOTE: This manuscript includes videos. Not all PDF readers support video. For desktop computers we recommend using Adobe Acrobat Reader. To view videos within a PDF on an iPad we recommend viewing in ezPDF Reader or PDF Expert. On desktop computers you may view videos full screen by clicking on a video, right click on the video, then choose Full Screen Multimedia. Abstract BAV occurs in the vast majority of patients. While in BAV has had resurgence in association with the dissem- many this clinical improvement is short-lived, a ma- ination of TAVR. The lack of clear mortality benefit from jority of patients feel improved symptoms for as long BAV does not translate to lack of efficacy as a palliative as 1 year [1]. The utility of this therapy as a palliative therapy. BAV remains a useful bridge to surgical AVR or TAVR, and for symptom relief in patients who are not treatment is seen best among patients, who truly candidates for either AVR approach. It is also useful as a have no other option [2]. For example, the extreme diagnostic test for patients with low gradient-low out- risk patient, who is a candidate for neither surgical put AS, and for those with mixed pulmonary and aortic nor transcatheter AVR may undergo BAV periodically valvular disease. -
Coronary Artery Disease and Transcatheter Aortic Valve Replacement JACC State-Of-The-Art Review
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 74, NO. 3, 2019 ª 2019 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER THE PRESENT AND FUTURE JACC STATE-OF-THE-ART REVIEW Coronary Artery Disease and Transcatheter Aortic Valve Replacement JACC State-of-the-Art Review Laurent Faroux, MD, MSC, Leonardo Guimaraes, MD, Jérôme Wintzer-Wehekind, MD, Lucia Junquera, MD, Alfredo Nunes Ferreira-Neto, MD, David del Val, MD, Guillem Muntané-Carol, MD, Siamak Mohammadi, MD, Jean-Michel Paradis, MD, Josep Rodés-Cabau, MD ABSTRACT About one-half of transcatheter aortic valve replacement (TAVR) candidates have coronary artery disease (CAD), and controversial results have been reported regarding the effect of the presence and severity of CAD on clinical outcomes post-TAVR. In addition to coronary angiography, promising data has been recently reported on both the use of computed tomography angiography and the functional invasive assessment of coronary lesions in the work-up pre-TAVR. While waiting for the results of ongoing randomized trials, percutaneous revascularization of significant coronary lesions has been the routine strategy in TAVR candidates with CAD. Also, scarce data exists on the incidence, characteristics, and management of coronary events post-TAVR, and increasing interest exist on potential coronary access challenges in patients requiring coronary angiography/intervention post-TAVR. This review provides an updated overview of the current landscape of CAD in TAVR recipients, focusing on its prevalence, clinical impact, pre- and post-procedural evaluation and management, unresolved issues and future perspectives. (J Am Coll Cardiol 2019;74:362–72) © 2019 by the American College of Cardiology Foundation. -
Aortic Valve Disease and Associated Complex CAD: the Interventional Approach
Journal of Clinical Medicine Review Aortic Valve Disease and Associated Complex CAD: The Interventional Approach Federico Marin 1 , Roberto Scarsini 2, Rafail A. Kotronias 1 , Dimitrios Terentes-Printzios 1, Matthew K. Burrage 1 , Jonathan J. H. Bray 3, Jonathan L. Ciofani 4 , Gabriele Venturi 2, Michele Pighi 2, Giovanni L. De Maria 1 and Adrian P. Banning 1,* 1 Oxford Heart Centre, Oxford University Hospitals, NHS Trust, Oxford OX3 9DU, UK; [email protected] (F.M.); [email protected] (R.A.K.); [email protected] (D.T.-P.); [email protected] (M.K.B.); [email protected] (G.L.D.M.) 2 Department of Cardiology, University of Verona, 37129 Verona, Italy; [email protected] (R.S.); [email protected] (G.V.); [email protected] (M.P.) 3 Institute of Life Sciences 2, Swansea Bay University Health Board and Swansea University Medical School, Swansea SA2 8QA, UK; [email protected] 4 Department of Cardiology, Royal North Shore Hospital, Sydney 2065, Australia; [email protected] * Correspondence: [email protected] Abstract: Coronary artery disease (CAD) is highly prevalent in patients with severe aortic stenosis (AS). The management of CAD is a central aspect of the work-up of patients undergoing transcatheter aortic valve implantation (TAVI), but few data are available on this field and the best percutaneous coronary intervention (PCI) practice is yet to be determined. A major challenge is the ability to Citation: Marin, F.; Scarsini, R.; elucidate the severity of bystander coronary stenosis independently of the severity of aortic valve Kotronias, R.A.; Terentes-Printzios, stenosis and subsequent impact on blood flow. -
General Pulmonology Track (August 7, 2014) Ballroom a & B
PCCP MIDYEAR CONVENTION August 7, 2014, Crowne Plaza Ballroom A&B General Pulmonology Track (August 7, 2014) Ballroom A & B Time Topic Topic 9:00- Spirometry, Lung volumes, DLCO, Ventilator waveforms 9:45 airway resistance, MVV interpretation interpretation John Clifford E. Aranas, MD, FPCCP Celeste Mae L. Campomanes, MD, FPCCP 9:45- CPET interpretation Non-invasive ventilation trouble shooting 10:30 May N. Agno, MD, FPCCP Newell R. Nacpil, MD, FPCCP 10:30- Perioperative Pulmonary Evaluation for Sleep Study interpretation 11:15 Virginia S. delos Reyes, MD, FPCCP Lung Resection Vincent M. Balanag, Jr., MD, FPCCP 11:15- Perioperative Management for Non-thoracic Imaging in Pulmonary Medicine 12:00 Joseph Leonardo Z. Obusan, MD, FPCR Surgery Abundio A. Balgos, MD, FPCCP 12:00- Luncheon Symposium Luncheon Symposium 1:30 1:30- Ventilator waveforms Spirometry, Lung volumes, DLCO, airway 2:15 interpretation resistance, MVV interpretation Albert L. Rafanan, MD, FPCCP Rachel Lee-Chua, MD, FPCCP 2:15- Non-invasive ventilation trouble CPET interpretation 3:00 shooting Josephine Blanco-Ramos, MD, FPCCP Jubert P. Benedicto, MD, FPCCP 3:00- Perioperative Pulmonary Evaluation Sleep Study interpretation 3:45 for Lung Resection Aileen Guzman-Banzon, MD, FPCCP Benilda B. Galvez, MD, FPCCP 3:45- Perioperative Management for Non- Imaging in Pulmonary Medicine 4:30 thoracic Surgery Maria Lourdes S. Badion, MD, FPCR Eileen G. Aniceto, MD, FPCCP LEARNING OBJECTIVES Spirometry, Lung volumes, DLCO, airway resistance, MVV interpretation 1. Specify the indications for pulmonary function testing. 2. Describe how the following pulmonary function tests are performed a. Spirometry i. lung volumes ii. DLCO iii. airway resistance iv. -
Regarding the SARS Cov-2 Pandemic
Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic REVISED: August 19, 2020 An international group of ISHLT members representing Infectious Diseases, Pulmonology, Cardiology, Cardiothoracic Surgery and Pharmacy was appointed by the Executive Board of the ISHLT to discuss frequently asked questions related to the current pandemic caused by SARS- CoV-2 (virus) causing the disease coronavirus disease 2019 (COVID-19). The group has met frequently to update this document as more data and experience become available. This guidance is pertinent to care providers of patients with chronic lung/ heart disease and transplant, mechanical circulatory support, and pulmonary vascular disease. NEW INFORMATION IN THIS REVISION: - updated donor and recipient selection for cardiothoracic transplant - lung transplant listing criteria for COVID-19 related acute respiratory distress syndrome CONTRIBUTORS: Chair: Saima Aslam Infectious Diseases: Lara Danziger-Isakov, Me-Linh Luong, Shahid Husain, Fernanda P. Silveira, Paolo Grossi Cardiology: Eric Adler, Marta Farrero, Maria Frigerio, Enrico Ammirati, Luciano Potena, Mandeep R. Mehra, Jeffrey Teuteberg, Raymond Benza Pulmonology: Are Holm, Federica Meloni, Lianne Singer, Erika Lease, Stuart Sweet, Christian Benden, Maria M. Crespo, Marie Budev, Peter Hopkins, Andrew Courtwright Cardiothoracic Surgery: Stephan Ensminger, Jan Gummert, Marcelo Cypel, Daniel Goldstein Pharmacy: Michael Shullo, Patricia Ging 1 INDEX 1. Risk factors and severity of COVID-19 Page 3 2. Reducing risk of infection with SARS-CoV-2 Pages 3-5 3. SARS-CoV-2 testing Page 5-6 4. Management of a patient with chronic lung/heart disease and Pages 6-8 transplant, mechanical circulatory support or pulmonary vascular disease with confirmed COVID-19 5. -
Variability in Anesthesia Models of Care in Cardiac Surgery
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 25 November 2020 doi:10.20944/preprints202010.0085.v2 Communication Variability in Anesthesia Models of Care In Cardiac Surgery Dianne McCallister 1, Bethany Malone 2 , Jennifer Hanna3, and Michael S Firstenberg 3,* 1 Diagnosis Well, Inc, Greenwood Village, Colorado, USA; [email protected]. 2 Department of Surgery, Summa Akron City Hospital, Akron, Ohio, USA; [email protected]. 3 Department of Cardiothoracic and Vascular Surgery, The Medical Center of Aurora, Aurora, Colorado, USA; [email protected]. * Correspondence: [email protected] Abstract: The operating room in a cardiothoracic surgical case is a complex environment, with multiple handoffs often required by staffing changes, and can be variable from program to program. This study was done to characterize what types of practitioners provide anesthesia during cardiac operations to determine the variability in this aspect of care. A survey was sent out via a list serve of members of the cardiac surgical team. Responses from 40 programs from a variety of countries showed variability across every dimension requested of the cardiac anesthesia team. Given that anesthesia is proven to have influence on the outcome of cardiac procedures, this study indicates the opportunity to further study how this variability influences outcomes, and to identify best practices. Keywords: Cardiothoracic Surgery; Anesthesia Staffing Models; Outcomes; Operating Room Staffing; Handoffs; Quality; Communication 1. Introduction The operating room is a complex environment, with multiple team members, many of whom may move on and off the team based on shifts and other factors. The use of handoffs is a common procedure that can be employed to try to create continuity of care. -
PQI #13 Angina Without Procedure Admission Rate
AHRQ Quality Indicators Web Site: http://www.qualityindicators.ahrq.gov PQI #13 Angina without Procedure Admission Rate Numerator All discharges of age 18 years and older with ICD-9-CM principal diagnosis code for angina. Include ICD-9-CM diagnosis codes: 4111 INTERMED CORONARY SYND 4130 ANGINA DECUBITUS 41181 CORONARY OCCLSN W/O MI 4131 PRINZMETAL ANGINA 41189 AC ISCHEMIC HRT DIS NEC 4139 ANGINA PECTORIS NEC/NOS See Prevention Quality Indicators Appendices: • Appendix A – Admission Codes for Transfers Exclude cases: • transfer from a hospital (different facility) • transfer from a skilled Nursing Facility (SNF) or Intermediate Care Facility (ICF) • transfer from another health care facility • MDC 14 (pregnancy, childbirth, and puerperium) • with a code for cardiac procedure ICD-9-CM Cardiac procedure codes 0050 IMPL CRT PACEMAKER SYS OCT02- 3502 CLOSED MITRAL VALVOTOMY 0051 IMPL CRT DEFIBRILLAT OCT02- 3503 CLOSED PULMON VALVOTOMY 0052 IMP/REP LEAD LF VEN SYS OCT02- 3504 CLOSED TRICUSP VALVOTOMY 0053 IMP/REP CRT PACEMKR GEN OCT02- 3510 OPEN VALVULOPLASTY NOS 0054 IMP/REP CRT DEFIB GENAT OCT02- 3511 OPN AORTIC VALVULOPLASTY 0056 INS/REP IMPL SENSOR LEAD OCT06- 3512 OPN MITRAL VALVULOPLASTY 0057 IMP/REP SUBCUE CARD DEV OCT06- 3513 OPN PULMON VALVULOPLASTY 0066 PTCA OCT06- 3514 OPN TRICUS VALVULOPLASTY 1751 IMPLANTATION OF RECHARGEABLE 3520 REPLACE HEART VALVE NOS CARDIAC CONTRACTILITY MODULATION 3521 REPLACE AORT VALV-TISSUE [CCM], TOTAL SYSTEM OCT09- 3522 REPLACE AORTIC VALVE NEC 1752 IMPLANTATION OR REPLACEMENT OF 3523 REPLACE MITR VALV-TISSUE -
Balloon Aortic Valvuloplasty Ngozi C
& The ics ra tr pe a u i t i Agu and Syamasundar Rao, Pediat Therapeut 2012, S5 d c e s P Pediatrics & Therapeutics DOI: 10.4172/2161-0665.S5-004 ISSN: 2161-0665 Research Article Open Access Balloon Aortic Valvuloplasty Ngozi C. Agu and P. Syamasundar Rao* Department of Pediatrics, Division of Pediatrics Cardiology, University of Texas Health Science Center at Houston, Houston Texas, USA Abstract Following the description by Lababidi in 1983 of balloon aortic valvuloplasty, it has been adopted by several groups of workers for relief of aortic valve stenosis. The indications for the procedure are peak-to-peak systolic pressure gradients in excess of 50 mmHg with symptoms or ECG changes or a gradient greater than 70 mmHg irrespective of the symptoms or ECG changes. One or more balloon dilatation catheters are placed across the aortic valve percutaneously, over extra-stiff guide wire (s) and the balloon (s) inflated until waist produced by the stenotic valve is abolished. A balloon/annulus ratio is 0.8 to 1.0 is recommended. While trans-femoral arterial route is the most commonly used for balloon aortic valvuloplasty, trans-umbilical arterial or venous or trans-venous routes are preferred in neonate and young infants to avoid femoral arterial injury. Reduction of peak-to-peak systolic pressure gradient along with a fall in left ventricular peak systolic and end- diastolic pressures is seen after balloon aortic valvuloplasty in the majority of patients. Significant aortic insufficiency, though rare, may develop, particularly in the neonate. At intermediate-term follow-up, peak-to-peak gradients, at repeat cardiac catheterization and noninvasive Doppler gradients remain low for the group as a whole. -
Nitroglycerin in Cardiac Arrest Before Transcatheter Aortic Valve Implantation
DOI: 10.14744/ejmi.2019.2101 EJMI 2019;3(1):81-83 Case Report Nitroglycerin in Cardiac Arrest Before Transcatheter Aortic Valve Implantation Mustafa Zungur Department of Cardiology, Cigli Kent Hospital, Izmir, Turkey Abstract We present a 75-year-old male patient having aortic stenosis for which transcatheter aortic valve implantation (TAVI) had been planned. Patient developed cardiac arrest before TAVI. Cardiopulmonary resuscitation (CPR) followed by 10 mg intravenous bolus nitroglycerine administration at the 40 min was per-formed. Patient was conscious and cooper- ated at the 80th hour following CPR and was stable hemodynamically. TAVI was applied on the 8th day and patient was discharged to home from the cardiology clinic on the 6th day after TAVI. Bolus nitroglycerine administration may have a place in CPR protocols, which needs to be evaluated in further clinical studies. Keywords: Aortic Stenosis, nitroglycerine, transcatheter aortic valve implantation Cite This Article: Zungur M. Nitroglycerin in Cardiac Arrest Before Transcatheter Aortic Valve Im-plantation. EJMI 2019;3(1):81-83. round 45% of deaths throughout the world develop The patient reviewed the case report and gave written per- Adue to cardiovascular diseases among which aortic mission for the authors to pub-lish the report. stenosis is an important cause for cardiac mortality and morbidity.[1] Transcatheter aortic valve implantation (TAVI) Case Report is the preferred therapeutic option in the treat-ment of aor- TTAVI application had been planned for a 75-year-old male tic stenosis, particularly for patients with multiple severe patient having severe aortic stenosis. Standard laboratory comorbidities, for those having expected high periopera- tive mortality, or for those having contraindication for con- tests and consultations were made preoperatively. -
Minimally Invasive Tricuspid Valve Surgery
1992 Review Article on Minimally Invasive Cardiac Surgery Minimally invasive tricuspid valve surgery Abdelrahman Abdelbar^, Ayman Kenawy, Joseph Zacharias Department of Cardiothoracic surgery, Lancashire Heart Centre, Blackpool Teaching Hospital, Blackpool, UK Contributions: (I) Conception and design: A Abdelbar, J Zacharias; (II) Administrative support: J Zacharias; (III) Provision of study materials or patients: A Abdelbar, A Kenawy; (IV) Collection and assembly of data: A Abdelbar, A Kenawy; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Abdelrahman Abdelbar, FRSC C-Th. Department of Cardiothoracic Surgery, Lancashire Heart Centre, Blackpool Teaching Hospital, Whinny Heys Rd, Blackpool, UK. Email: [email protected]. Abstract: Tricuspid valve disease carries a very unfavorable prognosis when medically treated. Despite that, surgical intervention is still underperformed for tricuspid valve disease due to the reported high morbidity and mortality from a sternotomy approach. This had led to a shift towards maximizing medical therapy for right ventricular failure and, as a result, a more significant delay in surgical referrals with surgical risks when patients are finally referred. Tricuspid valve patients usually have other co-morbidities resulting from their systemic venous congestion and low flow cardiac output. Minimally invasive tricuspid valve surgery provides less tissue injury and, as a result, less trauma during surgery. This provides a hope for both patients and treating doctors to be more open for providing this procedure with less complications. Isolated minimally invasive tricuspid valve surgery is still not performed as widely as expected. This can be partly due to the adverse outcomes historically labelled to tricuspid valve surgery or by the long journey of learning the surgical team would need to commit to with a minimal access approach. -
Get Answers to Cardiothoracic Surgery Residency Faqs
Cardiothoracic Surgery Residency Frequently Asked Questions What percentage of graduating CT surgery fellows (integrated vs traditional) are getting jobs within the first 12 months after graduation? Overall, the job market is doing very well. Anecdotal evidence from the University of Michigan, MD Anderson, and Emory shows that in the past 2 years, CT surgery residents applying for cardiac surgery (private practice) and general thoracic surgery (academic and private practice) positions have had a large increase in the number of job interviews. Current trainees are going on five to seven interviews each. The exact number of fellows being hired within 12 months is difficult to provide. The Thoracic Surgery Residents Association (TSRA) conducts a survey of all trainees during the In-Training Examination every spring. The survey asks those trainees who are actively looking for a job to identify how many job interviews they have had at the time of the survey. The question is broken up by the type of job that is being pursued (private practice, academic cardiac, academic general thoracic, etc.); data on the frequency of job interviews overall are not available. Among the respondents who were completing residency in 2016 who reported they were seeking employment, the percentage of trainees who had at least one job interview by spring 2016 by job type is: 71% mixed adult cardiac/general thoracic private practice 41% general thoracic private practice 49% adult cardiac private practice 29% mixed adult cardiac/general thoracic academic practice 51% general thoracic academic practice 58% adult cardiac academic practice 7% congenital heart surgery academic practice Some respondents may have been looking within multiple types of jobs (i.e., both a thoracic private practice and a thoracic academic practice), so the true percentage of job interviews for each trainee may be higher.